Blood and Tissue Biomarkers in Prostate Cancer: State of the Art

Urologic Clinics of North America

Volumn 37, Issue 1, 2010, Pages 131-141

  Fiorentino, Michelangelo ^a,b   Capizzi, Elisa ^b   Loda, Massimo ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Blood biomarkers; Molecular pathology; Prostate cancer; Tissue biomarkers

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; CAVEOLIN; CAVEOLIN 1; CHOLESTEROL; DNA; FATTY ACID SYNTHASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P110; RAPAMYCIN DERIVATIVE; S6 KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CANCER STEM CELL; CHROMOSOME 8; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY;

BIOLOGICAL MARKERS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 75449105857     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.11.006     Document Type: Review

References (110)

1. Stark J.R., Perner S., Stampfer M.J., et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. J Clin Oncol 27 21 (2009) 3459-3464
2. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 13 (2009) 1320-1328
3. Andriole G.L., Crawford E.D., Grubb III R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 13 (2009) 1310-1319
4. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 36 (2005) 9067-9072
5. Camp R.L., Neumeister V., and Rimm D.L. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 26 34 (2008) 5630-5637
6. Wells W.A., Barker P.E., MacAulay C., et al. Validation of novel optical imaging technologies: the pathologists' view. J Biomed Opt 12 5 (2007) 051801
7. Byers R.J., Di Vizio D., O'connell F., et al. Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn 9 1 (2007) 20-29
8. Febbo P.G. Genomic approaches to outcome prediction in prostate cancer. Cancer 115 Suppl 13 (2009) 3046-3057
9. Lee Jr. J.T., Steelman L.S., and McCubrey J.A. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64 22 (2004) 8397-8404
10. Lee J.T., Lehmann B.D., Terrian D.M., et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 7 12 (2008) 1745-1762
11. Sarker D., Reid A.H., Yap T.A., et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15 15 (2009) 4799-4805
12. Yoshimoto M., Cunha I.W., Coudry R.A., et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97 5 (2007) 678-685
13. Sircar K., Yoshimoto M., Monzon F.A., et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218 4 (2009) 505-513
14. McMenamin M.E., Soung P., Perera S., et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59 17 (1999) 4291-4296
15. Bertram J., Peacock J.W., Fazli L., et al. Loss of PTEN is associated with progression to androgen independence. Prostate 66 9 (2006) 895-902
16. Ayala G., Thompson T., Yang G., et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10 19 (2004) 6572-6578
17. Kreisberg J.I., Malik S.N., Prihoda T.J., et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64 15 (2004) 5232-5236
18. Majumder P.K., Febbo P.G., Bikoff R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 6 (2004) 594-601
19. Morgan T.M., Koreckij T.D., and Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9 2 (2009) 237-249
20. Hermans K.G., van Marion R., van Dekken H., et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66 22 (2006) 10658-10663
21. Ribeiro F.R., Henrique R., Hektoen M., et al. Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer 5 (2006) 33
22. Bethel C.R., Faith D., Li X., et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res 66 22 (2006) 10683-10690
23. Magee J.A., Abdulkadir S.A., and Milbrandt J. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell 3 (2003) 273-283
24. Ouyang X., DeWeese T.L., Nelson W.G., et al. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 65 15 (2005) 6773-6779
25. Song H., Zhang B., Watson M.A., et al. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 28 37 (2009) 3307-3319
26. Korkmaz C.G., Korkmaz K.S., Manola J., et al. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J Urol 172 3 (2004) 1134-1139
27. Cher M.L., Bova G.S., Moore D.H., et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56 13 (1996) 3091-3102
28. Freedman M.L., Haiman C.A., Patterson N., et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 103 (2006) 14068-14073
29. Pal P., Xi H., Guha S., et al. Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry. Prostate 69 14 (2009) 1548-1556
30. Pomerantz M.M., Beckwith C.A., Regan M.M., et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 69 13 (2009) 5568-5574
31. Sato K., Qian J., Slezak J.M., et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 91 18 (1999) 1574-1580
32. Ellwood-Yen K., Graeber T.G., Wongvipat J., et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 3 (2003) 223-238
33. Gurel B., Iwata T., Koh C.M., et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 9 (2008) 1156-1167
34. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 5748 (2005) 644-648
35. Mosquera J.M., Perner S., Genega E.M., et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14 11 (2008) 3380-3385
36. Attard G., Clark J., Ambroisine L., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27 3 (2008) 253-263
37. Perner S., Demichelis F., Beroukhim R., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66 17 (2006) 8337-8341
38. Darnel A.D., Lafargue C.J., Vollmer R.T., et al. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 8 2 (2009) 125-130
39. Gopalan A., Leversha M.A., Satagopan J.M., et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69 4 (2009) 1400-1406
40. Attard G., Jameson C., Moreira J., et al. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. J Clin Pathol 62 4 (2009) 373-376
41. Tomlins S.A., Laxman B., Dhanasekaran S.M., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448 7153 (2007) 595-599
42. Warburg O. On respiratory impairment in cancer cells. Science 124 3215 (1956) 269-270
43. Medes G., Paden G., and Weinhouse S. Metabolism of neoplastic tissues. XI. Absorption and oxidation of dietary fatty acids by implanted tumors. Cancer Res 17 2 (1957) 127-133
44. Vander Heiden M.G., Cantley L.C., and Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 5930 (2009) 1029-1033
45. Menendez J.A., and Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7 10 (2007) 763-777
46. Hatzivassiliou G., Zhao F., Bauer D.E., et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8 4 (2005) 311-321
47. Wellen K.E., Hatzivassiliou G., Sachdeva U.M., et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324 5930 (2009) 1076-1080
48. Wang C., Xu C., Sun M., et al. Acetyl-CoA carboxylase-alpha inhibitor TOFA induces human cancer cell apoptosis. Biochem Biophys Res Commun 385 3 (2009) 302-306
49. Baron A., Migita T., Tang D., et al. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem 91 1 (2004) 47-53
50. Migita T., Ruiz S., Fornari A., et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 101 7 (2009) 519-532
51. Little J.L., Wheeler F.B., Fels D.R., et al. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 67 3 (2007) 1262-1269
52. Fiorentino M., Zadra G., Palescandolo E., et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 88 12 (2008) 1340-1348
53. Siddiqui I.A., Malik A., Adhami V.M., et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27 14 (2008) 2055-2063
54. Kuhajda F.P., Pizer E.S., Li J.N., et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 97 7 (2000) 3450-3454
55. Zhuang L., Kim J., Adam R.M., et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115 4 (2005) 959-968
56. Williams T.M., Hassan G.S., Li J., et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 280 26 (2005) 25134-25145
57. Di Vizio D., Sotgia F., Williams T.M., et al. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther 6 8 (2007) 1263-1268
58. Polyak K., and Hahn W.C. Roots and stem: stem cells in cancer. Nat Med 12 3 (2006) 296-300
59. Gu G., Yuan J., Wills M., et al. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67 10 (2007) 4807-4815
60. Patrawala L., Calhoun T., Schneider-Broussard R., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25 (2006) 1696-1708
61. Collins A.T., Berry P.A., Hyde C., et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65 (2005) 10946-10951
62. Maitland N.J., and Collins A.T. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26 (2008) 2862-2870
63. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356 (2007) 217-226
64. Hurt E.M., Kawasaki B.T., Klarmann G.J., et al. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98 4 (2008) 756-765
65. Klarmann G.J., Hurt E.M., and Mathews L.A. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26 5 (2009) 433-446
66. Palapattu G.S., Wu C., Silvers C.R., et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 69 7 (2009) 787-798
67. Signoretti S., and Loda M. Prostate stem cells: from development to cancer. Semin Cancer Biol 17 3 (2007) 219-224
68. Pomerantz M.M., Freedman M.L., and Kantoff P.W. Genetic determinants of prostate cancer risk. BJU Int 100 2 (2007) 241-243
69. Lieberfarb M.E., Lin M., Lechpammer M., et al. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res 63 16 (2003) 4781-4785
70. Tørring N., Borre M., Sørensen K.D., et al. Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. Br J Cancer 96 3 (2007) 499-506
71. Liu W., Sun J., Li G., et al. Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Cancer Res 69 6 (2009) 2176-2179
72. Ross R.W., Oh W.K., Xie W., et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26 6 (2008) 842-847
73. Hittelman A., Sridharan S., Roy R., et al. Evaluation of whole genome amplification protocols for array and oligonucleotide CGH. Diagn Mol Pathol 16 4 (2007) 198-206
74. Paris P.L., Andaya A., Fridlyand J., et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13 13 (2004) 1303-1313
75. Ishkanian A.S., Mallof C.A., Ho J., et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 69 10 (2009) 1091-1100
76. Huang J., Pang J., Watanabe T., et al. Whole genome amplification for array comparative genomic hybridization using DNA extracted from formalin-fixed, paraffin-embedded histological sections. J Mol Diagn 11 2 (2009) 109-116
77. Schweiger M.R., Kerick M., Timmermann B., et al. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One 4 5 (2009) e5548
78. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 5439 (1999) 531-537
79. Lapointe J., Li C., Higgins J.P., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101 3 (2004) 811-816
80. Bibikova M., Chudin E., Arsanjani A., et al. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 89 6 (2007) 666-672
81. Nakagawa T., Kollmeyer T.M., Morlan B.W., et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 3 5 (2008) e2318
82. Sidransky D. Circulating DNA: what we know and what we need to learn. Ann N Y Acad Sci 906 (2000) 1-4
83. Holdenrieder S., Stieber P., Bodenmüller H., et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 95 (2001) 114-120
84. Sozzi G., Conte D., Leon M., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21 21 (2003) 3902-3908
85. Holdenrieder S., Stieber P., von Pawel J., et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 10 18 (2004) 5981-5987
86. Stroun M., Maurice P., Vasioukhin V., et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 906 (2000) 161-168
87. Papadopoulou E., Davilas E., Sotiriou V., et al. Cell-free DNA in plasma as a new molecular marker for prostate cancer. Oncol Res 14 (2004) 439-445
88. Boddy J.L., Gal S., Malone P.R., et al. Prospective study on quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate diseases. Clin Cancer Res 11 (2005) 1394-1399
89. Chun F.K., Muller I., Lange I., et al. Circulating tumor-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 98 (2006) 544-548
90. Altimari A., Grigioni A.D., Benedettini E., et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 129 5 (2008) 756-762
91. Schwarzenbach H., Alix-Panabières C., Müller I., et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15 3 (2009) 1032-1038
92. Schwarzenbach H., Chun F.K., Lange I., et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer 120 7 (2007) 1465-1471
93. Müller I., Urban K., Pantel K., et al. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia. Ann N Y Acad Sci 1075 (2006) 222-229
94. Schwarzenbach H., Chun F.K., Müller I., et al. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int 102 2 (2008) 253-258
95. Pantel K., Brakenhoff R.H., and Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8 5 (2008) 329-340
96. Riethdorf S., Wikman H., and Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 123 9 (2008) 1991-2006
97. Panteleakou Z., Lembessis P., Sourla A., et al. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 15 3-4 (2009) 101-114
98. Wood Jr. D.P., and Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 15 12 (1997) 3451-3457
99. Berg A., Berner A., Lilleby W., et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 120 8 (2007) 1603-1609
100. Köllermann J., Weikert S., Schostak M., et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 26 30 (2008) 4928-4933
101. Kantoff P.W., Halabi S., Farmer D.A., et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol 19 12 (2001) 3025-3028
102. Ross R.W., Manola J., Hennessy K., et al. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res 11 14 (2005) 5195-5198
103. Danila D.C., Heller G., Gignac G.A., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13 23 (2007) 7053-7058
104. de Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14 19 (2008) 6302-6309
105. Goodman Jr. O.B., Fink L.M., Symanowski J.T., et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev 18 6 (2009) 1904-1913
106. Olmos D., Arkenau H.T., Ang J.E., et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 20 1 (2009) 27-33
107. Davis J.W., Nakanishi H., Kumar V.S., et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 179 6 (2008) 2187-2191
108. Attard G., Swennenhuis J.F., Olmos D., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69 7 (2009) 2912-2918
109. Leversha M.A., Han J., Asgari Z., et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 15 6 (2009) 2091-2097
110. Holcomb I.N., Grove D.I., Kinnunen M., et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 68 14 (2008) 5599-5608